Jan-Paul Simard - 26 Oct 2026 Form 4 Insider Report for XBiotech Inc. (XBIT)

Reporting relationship: Co-Chief Executive Officer
Issuer ticker: XBIT
Reported as of: 26 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Oct 2026, 15:32:06 UTC
Prior SEC filing: 28 Oct 2026
Source filing: View source filing
Reporting owner signature: Jan-Paul Simard

Filing notes and source

Key filing fact

Jan-Paul Simard filed Form 4 for XBiotech Inc. (XBIT) on 28 Oct 2026.

Key facts

This page summarizes Jan-Paul Simard's Form 4 filing for XBiotech Inc. (XBIT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Oct 2026, 15:32.

Change

Previous filing in this sequence was filed on 28 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002162361 Primary reporting owner

Simard Jan-Paul

Relationship: Co-Chief Executive Officer
Address: 5217 WINNEBAGO LN, AUSTIN, TX 78744, AUSTIN, UNITED STATES
Signature: Jan-Paul Simard
Signature date: 28 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XBIT transaction Derivative

Stock Option

Award

Transaction value
Shares: +2,000,000
Change %
Price: $0.000000^*
Shares after: 2,000,000
Date: 26 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000,000
Exercise price: $1.85

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

On October 26, 2026 (the "Grant Date"), the reporting person was granted options to purchase 2,000,000 shares of the Company's common stock under the Company's 2025 Equity Incentive Plan, at an exercise price equal to the Nasdaq closing price on the Grant Date. The Options expire ten years after the Grant Date. One-sixth (1/6) of the Options vest on the 180th day following the Grant Date, with an additional one-sixth (1/6) vesting every six months thereafter, subject to the terms of the Executive Employment Agreement.